1st Rare and Genetic Neurodegenerative Drug Development Summit 2022
June 22 - 23, 2022 Completed
Nobody has claimed this event yet.
Organizers who claim their event pages can update listing details, add photos, answer to reviews, view click reports and more.Claim your free event listing
Defining Translational Strategies to Ensure Clinical Success in Rare, Genetically Defined Populations
Advance Life-Changing Therapies for Adolescents and Adults With Rare Neurological Disorders
Welcome to the 1st Rare and Genetic Neurodegenerative Drug Development Summit! This trailblazing meeting will be discussing, debating and exploring pivotal rare and genetic neurodegenerative disease research making industry news headlines.
Pioneers in this exclusive industry are convening online, this June, to network and learn from experts in pharma, biotech and academia. The inaugural Rare and Genetic Neurodegenerative Drug Development Summit is hosting enriched, cross-sponsor discussions to re-shape and guide strategic and translational decision-making targeting genetically-defined populations.
Speakers: Anka G. Ehrhardt, Director, Cell-Based Assays / Analytical Research and Development, Merck, Christopher Missling, President and Chief, Executive Officer, Anavex Life Sciences, David Theron, Development Director in Neurology, Servier, Eline Appelmans, Director - Neuroscience Research, Foundation for the National Institutes of Health, Eric Schaeffer, Chief Scientific Officer, Paros Bio, Erin Rosenbaugh, FNIH Project Lead, Neuroscience Research Partnerships, George Tetz, Chief Executive Officer, Human Microbiology Institute, Greg Smiley, Founder and Chief Executive Officer, Adira Foundation, Gregory Stewart, Executive Consultant, Alchemy Neuroscience, Joff Mosakawa, President, Diligentsia, Jose Palma, Medical Director - Translational Medicine - Neuroscience and Neuromuscular Disorders, Novartis, Lingzhi Zhao, Senior Director - Gene Therapy and Transnational Discovery Gene Therapy, AGTC, Maya Chopra, Director, Translational Genomic Medicine, Rosamund Stone Zander Translational Neuroscience Center, Peter Bialek, Head of Translational Biology, Triplet Therapeutics, Robert Fremeau, Chief Scientific Officer, Vyant bio, Timothy Hammond, Lab Head, Sanofi, Yan Ni, Executive Director, Biomarkers and Precision Medicine, Passage Bio
Time: 08:50 - 16:00
Reviews are public and modifiable.